<?xml version="1.0" encoding="UTF-8"?>
<document id="30061414">
	<sentence id="s1" text="The action of the collagen binding receptor tyrosine kinase (RTK) discoidin domain receptor 2 (peptidyl-tyrosine phosphorylation) in both tumor and tumor stromal cells has been established as critical for breast cancer metastasis.">
		<entity id="s1.e1" charOffset="95-128"
			type="GO" text="peptidyl-tyrosine phosphorylation" ontology_id="GO_0018108"/>
		<entity id="s1.e2" charOffset="138-143"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s1.e3" charOffset="212-218"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
	</sentence>
	<sentence id="s2" text="By targeting peptidyl-tyrosine phosphorylation, WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs.">
		<entity id="s2.e1" charOffset="13-46"
			type="GO" text="peptidyl-tyrosine phosphorylation" ontology_id="GO_0018108"/>
		<entity id="s2.e2" charOffset="64-69"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
	<sentence id="s3" text="These findings represent an approach to inhibiting tumor-stromal interactions and support the development of allosteric inhibitors of peptidyl-tyrosine phosphorylation, such as WRG-28, as a promising approach to antimetastasis treatment">
		<entity id="s3.e1" charOffset="51-56"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s3.e2" charOffset="134-167"
			type="GO" text="peptidyl-tyrosine phosphorylation" ontology_id="GO_0018108"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
</document>
